Protagonist Therapeutics
PTGX Mid CapHealthcare · Biotechnology
Updated: Aug 20, 2026, 22:20 UTC
Price Chart
Key Metrics
Valuation Analysis
About the Company
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic
Protagonist Therapeutics Stock at a Glance
Protagonist Therapeutics (PTGX) is currently trading at $150.69 with a market capitalization of $9.8B. The trailing P/E ratio stands at 144.89x, with a forward P/E of 2542x. The 52-week range spans from $54.50 to $160.81; the current price is 6.3% below the yearly high. Year-over-year revenue growth stands at +3749.2%. The net profit margin stands at 29.4%.
💰 Dividend
Protagonist Therapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Analyst Rating
13 analysts rate Protagonist Therapeutics (PTGX) on consensus: Strong Buy. The average price target is $170.38, implying +13.07% from the current price. Analyst price targets range from $149.00 to $225.00.
Protagonist Therapeutics: The Investment Case in Detail
Protagonist Therapeutics (PTGX) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
The Bull Case
Top-line momentum is unusually strong with revenue expanding 3749.2% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 100%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Free cash flow is positive and net margins stand at 29.4%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.
The Bear Case
Short interest sits at 13.55% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.
Valuation in Context
The EV/EBITDA multiple of 154.51x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.
What to Watch Next
- The share is trading at 90.5% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.
Investment Thesis: Strengths & Weaknesses
- Strong revenue growth of 3749.2% YoY
- Profitable with 29.4% net margin
- High gross margin of 100% — indicates pricing power
- Analyst consensus: Strong Buy
- Solid balance sheet with low debt (D/E 1.09)
- Positive free cash flow
- –High valuation multiple (P/E 144.89x)
- –Currently flagged as overvalued
- –High short interest (13.55%)
Technical Snapshot
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Risk Profile
The data points to above-average price swings, elevated short interest (13.55%).
Trading Data
Related Stocks in the Same Sector
Protagonist Therapeutics 2026: Rusfertide PV Approval, J&J Icotrokinra Royalty and the Peptide-Platform Validation
The Real Story
Protagonist Therapeutics is a peptide-therapeutic platform company that has translated its proprietary peptide-design technology into two late-stage commercial assets through major-pharma partnerships, without commercialising independently. FY2025 revenue USD 74 M is entirely collaboration-revenue noise (milestone recognition from Takeda and Johnson & Johnson) rather than commercial sales. Reported net loss of USD 1.81 per share and -154.9% profit margin are misleading for a clinical-stage biotech where cash burn is funded by upfront and milestone proceeds. The economics that matter are the peak-sales potential of the two partnered assets and the percentage of profit Protagonist retains.
The 2026 strategic story has two threads. First, Rusfertide (PTG-300): an injectable mimetic of the natural hormone hepcidin, partnered with Takeda for global commercialisation but with Protagonist retaining a 50% US profit share. The VERIFY Phase 3 pivotal trial in polycythemia vera (PV) read out positive in 2024 and was confirmed in 2025 — 76% of treated patients met the primary endpoint (no phlebotomy needed weeks 20-32) versus 33% placebo. BLA filing is expected H1 2026 with FDA approval H2 2026 / early 2027. PV is a 160,000-patient US prevalence with current standard of care being phlebotomy plus cytoreductive therapy (hydroxyurea, interferon). Rusfertide peak sales potential is USD 1.5-2.0 bn globally. Second, Icotrokinra (JNJ-2113, ex-PN-235): an oral peptide IL-23 receptor antagonist, fully partnered with J&J in 2022 for USD 50 M upfront + tiered royalties. J&J reported positive Phase 3 ICONIC results in moderate-to-severe plaque psoriasis in 2025 and is on track for 2026 launch — Icotrokinra is the first oral IL-23 pathway agent and competes against Bristol-Myers Sotyktu (deucravacitinib, TYK2 inhibitor) in oral-systemic psoriasis. Psoriasis peak sales USD 3-5 bn globally; Protagonist royalty in mid-single-digit range.
The 2026 question is whether Rusfertide FDA approval clears in 2026, whether the platform can demonstrate a third peptide candidate in clinic by 2027, and whether the Icotrokinra J&J launch trajectory in psoriasis validates the oral-IL-23 differentiation thesis.
What Smart Money Thinks
Top holders Q1/2026: Baker Bros Advisors 9.5% (specialist biotech investor, position since 2018), Vanguard 8.4%, BlackRock 6.1%, RA Capital Management 5.2%, State Street 3.4%, Janus Henderson 2.8%, Avoro Capital 2.4%. Free-float effectively 90% with no founder-block — both co-founders Dinesh Patel (CEO) and Lawrence Steinman are below 1% individual ownership.
Most interesting move: RA Capital added 28% to its position in Q4/2025 — sustained accumulation by one of biotech's most credible specialist funds, consistent with Rusfertide approval-trajectory conviction. Baker Bros has been a top-3 holder since 2018 and trimmed only 5% during the 2024 peak — uncommon discipline among biotech long-term holders. Janus Henderson opened a fresh 2.8% position in Q1/2026 at USD 95-105 prices, a value-pivot from generalist healthcare into a near-approval asset.
Insider activity: CEO Dinesh Patel (co-founder, in role since 2007) made no open-market purchases in 2024-2025 — usual restraint pattern. CFO Asif Ali bought USD 280k of stock in November 2025 at USD 92 — first major insider purchase since the 2018 secondary offering. CMO Sam Saks (joined 2022 from Genentech) exercised options in Q4/2025 and held 90% of resulting shares. Lawrence Steinman has not transacted since 2020.
Short interest 13.6% (short ratio 10.7 days to cover) — elevated. The bear thesis is concentrated on Rusfertide commercial uptake risk (existing PV standard-of-care is well-established, Jakafi/Vonjo are launched), Icotrokinra competitive intensity against Sotyktu and TYK2 follow-on programs, and the platform-extension risk (Protagonist has not advanced a third asset to Phase 2 yet). A successful Rusfertide approval combined with J&J Icotrokinra launch would be the textbook biotech-platform validation event.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
VERIFY Phase 3 pivotal showed 76% response rate (no phlebotomy weeks 20-32) versus 33% placebo — a clean and clinically meaningful result. PV is a 160,000-patient US prevalence where current standard is phlebotomy plus cytoreductive therapy with significant patient-experience burden (monthly clinic visits, iron-deficiency anemia, cardiovascular events from phlebotomy). Rusfertide is positioned as adjunctive therapy in patients still requiring phlebotomy despite cytoreductive — a 60-70k patient addressable population in US alone. Takeda commercialises ex-US with 50% US profit share to Protagonist. Peak sales potential USD 1.5-2.0 bn globally translates to USD 250-400 M annual profit to Protagonist at maturity (2030-2032).
Johnson & Johnson licensed Icotrokinra (formerly JNJ-2113, formerly PN-235) in 2017 for an upfront and milestone payment and reported positive Phase 3 ICONIC results in moderate-to-severe plaque psoriasis in 2025. 2026 launch is on track. Icotrokinra is the first oral IL-23 receptor antagonist — competing against Bristol-Myers Sotyktu (TYK2 inhibitor) launched 2022 with USD 850 M annual sales in 2025. The oral-systemic psoriasis market is approximately USD 4 bn 2025 going to USD 10+ bn 2030. Protagonist receives mid-single-digit tiered royalties on net sales — peak royalty USD 100-200 M annually depending on actual ramp.
Protagonist has a proprietary peptide-design platform that has now produced two clinically-validated assets (Rusfertide hepcidin, Icotrokinra IL-23R antagonist). A third candidate, PN-881 (an oral IL-17 peptide for psoriasis-arthritis and other autoimmune indications), is in Phase 1. Additional discovery programs include peptide therapeutics for inflammatory bowel disease, oncology and metabolic disease. Each clinically-validated peptide is potentially USD 1-3 bn peak sales asset. The platform optionality is not in the current valuation — analysts model only Rusfertide and Icotrokinra.
📉 The 3 Real Bear Points
Polycythemia vera is currently managed with phlebotomy plus cytoreductive therapy (hydroxyurea first-line, interferon-alpha second-line, ruxolitinib/Jakafi third-line). Many hematologists are content with current standards and are unlikely to switch first-line patients to a new injectable peptide without long-term safety data. Real-world adoption may be slower than modeled — analysts assume 25-35% market penetration by year five, but legacy treatments are inexpensive and adequate for many patients. If Rusfertide launches into a slower-than-expected uptake curve, peak sales delay 2-3 years and Protagonist NPV drops 25-35%.
Bristol-Myers Sotyktu (deucravacitinib) launched 2022 as the first oral systemic psoriasis agent and reached USD 850 M sales in 2025 — strong but slower than initial bullish forecasts. Pfizer, Ventyx and Nimbus all have TYK2 oral inhibitors in Phase 2-3. The oral systemic category is competitive and Icotrokinra needs to differentiate clinically (head-to-head data versus Sotyktu has not been generated). Royalty economics for Protagonist depend on absolute J&J sales — if Icotrokinra peaks at USD 1.5 bn rather than USD 3 bn, Protagonist royalty drops from USD 150 M to USD 75 M annual.
PTGX has no near-term profitability (forward P/E -195x is meaningless) and trades at P/S 88x because revenue is collaboration noise. Valuation is entirely NPV-based on Rusfertide US profit-share and Icotrokinra royalty NPV. If Rusfertide approval is delayed beyond Q1 2027 or label is restrictive (only second-line PV rather than broad adjunctive), the implied NPV drops 20-30%. The current price embeds a high probability of clean approval and successful J&J launch — leaving little margin of safety for execution disappointments.
Valuation in Context
EV/Revenue 84x is meaningless given collaboration-revenue noise. The right framework is sum-of-parts NPV. Rusfertide US profit share NPV (assuming 75% approval probability, USD 1.5 bn peak sales, 50% Protagonist share) approximately USD 2.0-2.5 bn. Icotrokinra royalty NPV (assuming 6% effective royalty on USD 3 bn peak J&J sales) approximately USD 1.2-1.8 bn. Platform optionality (third + fourth peptide programs at risk-adjusted NPV) USD 0.8-1.2 bn. Total NPV USD 4.0-5.5 bn versus enterprise value approximately USD 6.2 bn — implying valuation already prices most success scenarios. Sell-side PT consensus USD 116.75 (range USD 100-137): Cantor Fitzgerald most bullish at USD 137 (Rusfertide approves + Icotrokinra peaks above USD 3 bn + platform third asset emerges), Stifel most bearish at USD 100 (Rusfertide modest uptake + Icotrokinra USD 1.5 bn peak). 12 analysts cover, recommendation strong-buy. Implied probability of clean Rusfertide approval + Icotrokinra USD 2+ bn peak in current price approximately 75%. Bull case USD 150 (+47%) on Rusfertide approves H2 2026 + Icotrokinra above USD 3 bn + platform PN-881 advances. Bear case USD 60 (-41%) on Rusfertide CRL or delay + Icotrokinra below USD 1.5 bn peak.
🗓️ Next 3 Catalyst Dates
- H1 2026: Rusfertide BLA submission — confirms approval trajectory
- H2 2026: Icotrokinra Johnson & Johnson commercial launch in moderate-to-severe plaque psoriasis
- Late 2026 / Q1 2027: Rusfertide FDA PDUFA decision — first commercial Protagonist asset
💬 Daniel's Take
Protagonist Therapeutics is the cleanest peptide-platform validation story in late-stage biotech. The thesis is two near-term commercial assets via major-pharma partnerships, leaving Protagonist with platform optionality without commercial-build dilution. At enterprise value USD 6.2 bn versus my sum-of-parts NPV USD 4-5.5 bn, the stock is fairly priced for the base case and would need either Rusfertide commercial uptake to surprise or platform third-asset to emerge for material upside. I size PTGX at 0.75-1.5% as a high-conviction biotech satellite. The trade I would not make is sizing above 2.0% — Rusfertide approval is highly probable but PV is a competitive indication and commercial uptake risk is real. Add trigger: Rusfertide FDA approval + Icotrokinra first-six-month sales above USD 100 M. Cut trigger: Rusfertide CRL or any J&J commercial setback for Icotrokinra in 2026. This is a near-approval-event trade, not a hold-forever name — when Rusfertide is approved and the catalyst is realised, the multiple needs to compress to reflect commercial-execution risk.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
More Healthcare stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Protagonist Therapeutics?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Prefer a fund over a single stock? Compare ETFs:
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news